Efficacy and Toxicity of Panitumumab After Progression on
Cetuximab and Predictive Value of MiR-31-5p in Metastatic
Wild-type KRAS Colorectal Cancer Patients

J 2016

Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients

KISS, Igor, Jitka MLČOCHOVÁ, Zbyněk BORTLÍČEK, Alexandr POPRACH, Jiří DRÁBEK et. al.

Basic information

Original name

Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients

Name in Czech

Efektivita a toxicita panitumumabu po progresi na cetuximabu a prediktivní význam MiR-31-5p u pacientů s metastatickým divokým KRAS colorektálním karcinomem

Authors

KISS, Igor (203 Czech Republic), Jitka MLČOCHOVÁ (203 Czech Republic, belonging to the institution), Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution), Alexandr POPRACH (203 Czech Republic), Jiří DRÁBEK (203 Czech Republic), Petra VYCHYTILOVÁ (203 Czech Republic, belonging to the institution), Marek SVOBODA (203 Czech Republic, belonging to the institution), Tomáš BÜCHLER (203 Czech Republic), Stanislav BATKO (203 Czech Republic), Aleš RYŠKA (203 Czech Republic), Marian HAJDÚCH (203 Czech Republic) and Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution)

Edition

Anticancer Research, Athens, INT INST ANTICANCER RESEARCH, 2016, 0250-7005

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Greece

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 1.937

RIV identification code

RIV/00216224:14740/16:00087634

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.21873/anticanres.11063

UT WoS

000384001800083

Keywords (in Czech)

KRAS; Metastatický kolorektální karcinom; cetuximab; miR-31-5p; microRNA; panitumumab

Keywords in English

KRAS; Metastatic colorectal cancer; cetuximab; miR-31-5p; microRNA; panitumumab

Abstract

V originále

Background: In metastatic colorectal cancer (mCRC), panitumumab is generally considered to be ineffective after the progression on cetuximab therapy. However, few studies have demonstrated that a small subset of mCRC patients may benefit from panitumumab in this setting. Patients and Methods: In our study, wild-type KRAS mCRC patients, enrolled into the nationwide Czech registry CORECT between January 2007 and December 2012, were screened for panitumumab therapy after progression on cetuximab. Results: We identified 26 mCRC in the registry with well documented progression on cetuximab in combination with irinotecan-based chemotherapy (FOLFIRI or irinotecan alone) who received panitumumab monotherapy. Partial response (PR) was achieved in 3 (11.5%) patients and stable disease (SD) in 7 (26.9%) patients after 8 weeks of therapy. Thirteen (50.0%) patients had evidence of progressive disease (PD) and in 3 (11.5%) cases response was not available. Furthermore, we confirmed that higher expression levels of newly described biomarker, miR-31-5p, in tumor are significantly associated with shorter progression-free survival (PFS) in patients treated with cetuximab (p=0.038); however, we did not observe association between miR-31-5p and response to panitumumab in mCRC patients after progression on cetuximab. Conclusion: It remains possible that a subset of mCRC patients may benefit from panitumumab after progression on cetuximab.

Links

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

NV16-31765A, research and development project

Name: Využití tkáňových/cirkulujících mikroRNA pro predikci léčebné odpovědi a zpřesnění restagingu karcinomu rekta po neoadjuvantní léčbě

TE02000058, research and development project

Name: Centrum kompetence pro molekulární diagnostiku a personalizovanou medicínu (Acronym: MOLDIMED)

Investor: Technology Agency of the Czech Republic

Citovat

KISS, Igor, Jitka MLČOCHOVÁ, Zbyněk BORTLÍČEK, Alexandr POPRACH, Jiří DRÁBEK, Petra VYCHYTILOVÁ, Marek SVOBODA, Tomáš BÜCHLER, Stanislav BATKO, Aleš RYŠKA, Marian HAJDÚCH and Ondřej SLABÝ. Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients. Anticancer Research. Athens: INT INST ANTICANCER RESEARCH, 2016, vol. 36, No 9, p. 4955-4959. ISSN 0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.11063.

@article{1362715,
   author = {Kiss, Igor and Mlčochová, Jitka and Bortlíček, Zbyněk and Poprach, Alexandr and Drábek, Jiří and Vychytilová, Petra and Svoboda, Marek and Büchler, Tomáš and Batko, Stanislav and Ryška, Aleš and Hajdúch, Marian and Slabý, Ondřej},
   article_location = {Athens},
   article_number = {9},
   doi = {http://dx.doi.org/10.21873/anticanres.11063},
   keywords = {KRAS; Metastatic colorectal cancer; cetuximab; miR-31-5p; microRNA; panitumumab},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients},
   url = {http://ar.iiarjournals.org/content/36/9/4955.abstract},
   volume = {36},
   year = {2016}
}

TY  - JOUR
ID  - 1362715
AU  - Kiss, Igor - Mlčochová, Jitka - Bortlíček, Zbyněk - Poprach, Alexandr - Drábek, Jiří - Vychytilová, Petra - Svoboda, Marek - Büchler, Tomáš - Batko, Stanislav - Ryška, Aleš - Hajdúch, Marian - Slabý, Ondřej
PY  - 2016
TI  - Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients
JF  - Anticancer Research
VL  - 36
IS  - 9
SP  - 4955-4959
EP  - 4955-4959
PB  - INT INST ANTICANCER RESEARCH
SN  - 02507005
KW  - KRAS
KW  - Metastatic colorectal cancer
KW  - cetuximab
KW  - miR-31-5p
KW  - microRNA
KW  - panitumumab
UR  - http://ar.iiarjournals.org/content/36/9/4955.abstract
L2  - http://ar.iiarjournals.org/content/36/9/4955.abstract
N2  - Background: In metastatic colorectal cancer (mCRC), panitumumab is generally considered to be ineffective after the progression on cetuximab therapy. However, few studies have demonstrated that a small subset of mCRC patients may benefit from panitumumab in this setting. Patients and Methods: In our study, wild-type KRAS mCRC patients, enrolled into the nationwide Czech registry CORECT between January 2007 and December 2012, were screened for panitumumab therapy after progression on cetuximab. Results: We identified 26 mCRC in the registry with well documented progression on cetuximab in combination with irinotecan-based chemotherapy (FOLFIRI or irinotecan alone) who received panitumumab monotherapy. Partial response (PR) was achieved in 3 (11.5%) patients and stable disease (SD) in 7 (26.9%) patients after 8 weeks of therapy. Thirteen (50.0%) patients had evidence of progressive disease (PD) and in 3 (11.5%) cases response was not available. Furthermore, we confirmed that higher expression levels of newly described biomarker, miR-31-5p, in tumor are significantly associated with shorter progression-free survival (PFS) in patients treated with cetuximab (p=0.038); however, we did not observe association between miR-31-5p and response to panitumumab in mCRC patients after progression on cetuximab. Conclusion: It remains possible that a subset of mCRC patients may benefit from panitumumab after progression on cetuximab.
ER  -

KISS, Igor, Jitka MLČOCHOVÁ, Zbyněk BORTLÍČEK, Alexandr POPRACH, Jiří DRÁBEK, Petra VYCHYTILOVÁ, Marek SVOBODA, Tomáš BÜCHLER, Stanislav BATKO, Aleš RYŠKA, Marian HAJDÚCH and Ondřej SLABÝ. Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients. \textit{Anticancer Research}. Athens: INT INST ANTICANCER RESEARCH, 2016, vol.~36, No~9, p.~4955-4959. ISSN~0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.11063.

Detailed Information on Publication Record